Suppr超能文献

抗血管生成药物通过损害牙龈成纤维细胞的增殖和迁移功能,加重了基于抗吸收药物的药物相关性颌骨坏死的程度。

Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts.

机构信息

Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, 22 Zhongguancun Nandajie Haidian District, Beijing, 100081, PR China.

National Clinical Research Center for Oral Diseases, Beijing, 100081, PR China.

出版信息

BMC Oral Health. 2023 May 27;23(1):330. doi: 10.1186/s12903-023-03034-7.

Abstract

BACKGROUND

Long-term use of anti-resorptive or anti-angiogenic drugs in cancer patients with odontogenic infections may lead to medication-related osteonecrosis of the jaw (MRONJ). This study investigated whether anti-angiogenic agents aggravate MRONJ occurrence in anti-resorptive-treated patients.

METHODS

The clinical stage and jawbone exposure of MRONJ patients caused by different drug regimens were analyzed to ascertain the aggravation effect of anti-angiogenic drugs on anti-resorptive drug-based MRONJ. Next, a periodontitis mice model was established, and tooth extraction was performed after administering anti-resorptive and/or anti-angiogenic drugs; the imaging and histological change of the extraction socket were observed. Moreover, the cell function of gingival fibroblasts was analyzed after the treatment with anti-resorptive and/or anti-angiogenic drugs in order to evaluate their effect on the gingival tissue healing of the extraction socket.

RESULTS

Patients treated with anti-angiogenic and anti-resorptive drugs had an advanced clinical stage and a bigger proportion of necrotic jawbone exposure compared to patients treated with anti-resorptive drugs alone. In vivo study further indicated a greater loss of mucosa tissue coverage above the tooth extraction in mice treated with sunitinib (Suti) + zoledronate (Zole) group (7/10) vs. Zole group (3/10) and Suti group (1/10). Micro-computed tomography (CT) and histological data showed that the new bone formation in the extraction socket was lower in Suti + Zole and Zole groups vs. Suti and control groups. In vitro data showed that the anti-angiogenic drugs had a stronger inhibitory ability on the proliferation and migration function of gingival fibroblasts than anti-resorptive drugs, and the inhibitory effect was obviously enhanced after combining zoledronate and sunitinib.

CONCLUSION

Our findings provided support for a synergistic contribution of anti-angiogenic drugs to anti-resorptive drugs-based MRONJ. Importantly, the present study revealed that anti-angiogenic drugs alone do not induce severe MRONJ but aggravate the degree of MRONJ via the enhanced inhibitory function of gingival fibroblasts based on anti-resorptive drugs.

摘要

背景

癌症患者长期使用抗吸收或抗血管生成药物治疗牙源性感染可能导致药物相关性下颌骨坏死(MRONJ)。本研究旨在探讨抗血管生成药物是否会加重抗吸收药物治疗的 MRONJ 患者的发病情况。

方法

分析不同药物方案治疗的 MRONJ 患者的临床分期和颌骨暴露情况,以确定抗血管生成药物对基于抗吸收药物的 MRONJ 的加重作用。接下来,建立牙周炎小鼠模型,在给予抗吸收和/或抗血管生成药物后进行拔牙,观察拔牙窝的影像学和组织学变化。此外,在给予抗吸收和/或抗血管生成药物后分析牙龈成纤维细胞的细胞功能,以评估其对拔牙窝牙龈组织愈合的影响。

结果

与单独接受抗吸收药物治疗的患者相比,同时接受抗血管生成和抗吸收药物治疗的患者的临床分期更晚,坏死颌骨暴露的比例更大。体内研究进一步表明,在舒尼替尼(Suti)+唑来膦酸(Zole)组(7/10)中,与唑来膦酸组(3/10)和舒尼替尼组(1/10)相比,小鼠拔牙后牙齿上方的黏膜组织覆盖有更大的损失。微计算机断层扫描(CT)和组织学数据显示,在 Suti+Zole 和 Zole 组以及 Suti 和对照组中,拔牙窝中的新骨形成较低。体外数据显示,与抗吸收药物相比,抗血管生成药物对牙龈成纤维细胞的增殖和迁移功能具有更强的抑制能力,并且在联合使用唑来膦酸和舒尼替尼后,抑制作用明显增强。

结论

本研究结果为抗血管生成药物对抗吸收药物治疗的 MRONJ 有协同作用提供了支持。重要的是,本研究表明,单独使用抗血管生成药物不会引起严重的 MRONJ,但会通过增强基于抗吸收药物的牙龈成纤维细胞的抑制功能来加重 MRONJ 的程度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e06c/10225109/0dadf7635343/12903_2023_3034_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验